

#### Welcome!

- Audio for this event is available via GlobalMeet<sup>®</sup> Internet streaming.
- Connect via Chrome.
- No telephone line is required.
- Computer speakers or headphones are necessary to listen to streaming audio.
- Limited dial-in lines are available.
   Please request a dial-in line via the Ask a Question box.
- This event is being recorded.

### **Troubleshooting Audio**


Audio from computer speakers breaking up?
Audio suddenly stop?
Click Refresh
– or –
Press F5





### **Troubleshooting Echo**

- Hear a bad echo on the call?
- Echo is caused by multiple browsers/tabs open to a single event (multiple audio feeds).
- Close all but one browser/tab and the echo will clear.




**Example of Two Browsers/Tabs Open in Same Event** 

### **Submitting Questions**

Type questions in the Ask a Question section on the left side.



Inpatient Value, Incentives, and Quality Reporting (VIQR) Outreach and Education Support Contractor



**Today's Presentation** 



# PCHQR Program: Overview of the End-of-Life Measures

**November 10, 2021** 

### **Speakers**

#### Tom Ross, MS

President – Ross Oncology Consulting Consultant to Alliance of Dedicated Cancer Centers (ADCC)

#### Kris McNiff Landrum, MPH

President – KM Healthcare Consulting Consultant to ADCC

#### Lisa Vinson, BS, BSN, RN

**Program Lead** 

PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program Inpatient Value, Incentives, and Quality Reporting (VIQR)

Outreach and Education Support Contractor

### **Purpose**

This presentation provides an overview of the End-of-Life (EOL) measures for the PCHQR Program, including measure specifications and confidential reporting.

### **Objectives**

#### PCHQR Program participants will be able to:

- Understand how PCHQR Program EOL measures were developed based on measure specifications.
- Locate and access the confidential fiscal year (FY) 2022 EOL reports in the Hospital Quality Reporting (HQR) System.
- Understand the contents of the confidential FY 2022 EOL reports and the steps to provide feedback.

### **Acronyms and Abbreviations**

ADCC	Alliance of Dedicated Cancer Centers	IP	inpatient
ASCO	American Society of Clinical Oncology	IPFQR	Inpatient Psychiatric Facilities Quality Reporting
ASCQR	Ambulatory Surgical Center Quality Reporting	IPPS	Inpatient Prospective Payment System
CMS	Centers for Medicare & Medicaid Services	IQR	Inpatient Quality Reporting
DOB	date of birth	LTCH	Long-Term Care Hospital
DOD	date of death	МВІ	Medicare Beneficiary Identifier
EOL	End of Life	NQF	National Quality Forum
FY	Fiscal Year	ОСМ	Oncology Care Measure
HARP	Health Care Quality Information Systems (HCQIS) Access Roles and Profile	ОР	outpatient
HCPCS	Healthcare Common Procedure Coding System	OQR	Outpatient Quality Reporting
НМО	Health Maintenance Organization	PCH	PPS-Exempt Cancer Hospital
HQR	Hospital Quality Reporting	PCHQR	PPS-Exempt Cancer Hospital Quality Reporting
HVBP	Hospital Value-Based Purchasing	PHE	Public Health Emergency
ICD-10- CM	International Classification of Diseases, Tenth Revision, Clinical Modification	PPS	Prospective Payment System
ICU	intensive care unit	VIQR	Value, Incentives, and Quality Reporting

Lisa Vinson, BS, BSN, RN, Program Lead, PCHQR Program, Inpatient VIQR Outreach and Education Support Contractor

#### **Background Information**

## **EOL Measures in the PCHQR Program**

NQF#	PCH#	Short Name	Full Name
0210	32	EOL-Chemo	Proportion of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life
0213	33	EOL-ICU	Proportion of Patients Who Died from Cancer Admitted to the ICU in the Last 30 Days of Life
0215	34	EOL-Hospice	Proportion of Patients Who Died from Cancer Not Admitted to Hospice
0216	35	EOL-3DH	Proportion of Patients Who Died from Cancer Admitted to Hospice for Less Than 3 Days

ICU=intensive care unit NQF=National Quality Forum

### **Background**

- The 4 EOL measures were finalized for inclusion in the PCHQR Program in the FY 2018 Inpatient Prospective Payment System (IPPS)/Long-Term Care Prospective Payment System (LTCH PPS) Final Rule (82 FR 38414 through 38420) for the FY 2020 program year.
- The data collection period was established as July 1, 2017, through June 18, 2020.

#### **EOL Care vs. Palliative Care**

- End-of-Life (EOL) care may be defined as "comprehensive care that addresses medical, emotional, spiritual, and social needs during the last stages of a person's terminal illness."
  - The NQF identified quality of EOL care as an area of care that continues to need improvement.
- Palliative care is generally defined as multi-faceted, holistic care that anticipates, prevents, and alleviates suffering.
- Both types of care can be provided when a patient is receiving hospice services, but it is not necessary to be admitted to hospice to receive such care.
- When death is imminent, providing less aggressive care can improve quality of life for patients.

## **Benefits of EOL and Palliative Care Services**

- When death is imminent, providing less aggressive care can improve quality of life for patients.
- Hospice is both a type of care team and a care philosophy, intended to enable patients to prepare for death while living a full life as much as possible.

## Proportion of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life (NQF #0210/PCH-32)

- Measure Category: Clinical Process
- Numerator: Cancer patients who received chemotherapy (regardless of whether for treatment or palliative purposes) in the last 14 days of life
- Denominator: Patients who died from cancer
- Seeks to assess the use of chemotherapy at the end-of-life with the intent to alleviate disease symptoms
- Evaluates how often chemotherapy is administered near the end of life in PCHs

## Proportion of Patients Who Died from Cancer Admitted to the ICU in the Last 30 Days of Life (NQF #0213/PCH-33)

- Measure Category: Intermediate Clinical Outcome
- Numerator: Number of patients who died from cancer and who were admitted to the ICU in the last 30 days of life
- **Denominator**: Patients who died from cancer.
- Assesses whether cancer patients were admitted to the ICU in the last 30 days of their lives
  - Particularly the frequency of end-of-life admissions to the ICU in this setting

### Proportion of Patients Who Died from Cancer Not Admitted to Hospice (NQF #0215/PCH-34)

- Measure Category: Clinical Process
- Numerator: Proportion of patients not enrolled in hospice
- **Denominator**: Patients who died from cancer
- Assesses the proportion of patients who died from cancer who were not admitted to hospice
- Seeks to evaluate whether patients were admitted to hospice or not

11/10/2021 1<sup>--</sup>

## Proportion of Patients Who Died from Cancer Admitted to Hospice for Less Than 3 Days (NQF #0216/PCH-35)

- Measure Category: Intermediate Clinical Outcome
- Numerator: Number of patients who died from cancer and spent fewer than 3 days in hospice
- <u>Denominator</u>: Number of patients who died from cancer and were admitted to hospice.
- Tied to the EOL-Hospice (PCH-34) measure to assess whether, if patients were admitted to hospice, they were admitted prior to or when death was immediately imminent.

Tom Ross, MS, President – Ross Oncology Consulting Kris McNiff, MPH, President – KM Healthcare Consulting

#### **EOL Measure Specifications**

### **Specifications Overview**

- The ADCC defined claims-only cohort identification and hospital attribution methodologies using the NQF-endorsed specifications.
  - The American Society of Clinical Oncology (ASCO) is measure steward.
- These are a claims-based measures.
- These specifications are intended to be used to measure performance at the hospital/facility level.
- While not part of the actual NQF-endorsed measures, nor for use in public display, a stratification method is provided to give hospitals more actionable data for internal performance improvement.

#### **Overall Process**

- 1. The overall population/cohort for the performance period is identified from the Medicare claims files.
- 2. Patients are attributed to hospitals.
- 3. <u>Denominator:</u> The patients attributed to each hospital/facility form the denominator for NQF #0210, #0213, and #0215. A further calculation is required to determined to denominator for NQF #0216.

### Overall Process (continued)

- 4. The numerator for each measure is then calculated.
- 5. The performance rate is then determined for each measure by dividing the numerator by the denominator.
- 6. The results for each hospital are then stratified into one of 3 groups:
  - Acute Hematology
  - Non-Acute Hematology
  - Solid Tumor

## Step 1: Identification of Population

The measure population includes all patients who died with a cancer diagnosis in the data collection period. The population is determined by the following (in order):

- Patients who died in the data collection period
- Patients aged 65 or greater as of the date of death
- Patients continuously enrolled in Medicare Parts A and B during the last 12 months before death
  - Patients enrolled in a health maintenance organization (HMO) in the 12 months before death are excluded

## Step 1: Identification of Population (continued)

- Patients with at least 2 cancer-related inpatient, outpatient or hospice visits during the 6 months before death. A cancer-related visit has a cancer diagnosis\* listed within the top 3 diagnoses.
  - For inpatient visits, each admission with cancer diagnosis within the top 3 diagnoses counts as one visit
  - For outpatient visits, a claim with a cancer diagnosis within the top 3 is counted; however, if there are multiple outpatient claims on the same calendar day, these contribute to a "claims day." A claims day equals one outpatient visit.

\*Cancer diagnosis is defined as ICD-10-CM range: C00.xx-97.xx, J91.01, R18.0, and D37.xx – D48.xx. Exclude C44.xx.

## Step 1: Population Flowchart

All unique patients in data collection period

Dead patients in data collection period

Age 65 or older

Continuous enrollment in Medicare Part A and B during 12 months before death

No HMO enrollment during last 12 months before death

At least 2 cancer related IP, OP, or hospice visits during the last 6 months before death

- 1. All the claims from inpatient claim, outpatient claim and hospice claim files
- 2. A cancer visit is defined as one day with claim(s) with cancer diagnosis at the top 3 diagnoses; each admission counts as a single visit
- 3. For outpatient services, "visit" is defined as one claims day
- 4. Cancer dx if ICD-10-CM range: C00.xx C97.xx, J91.0, R18.0, and D37.xx D48.xx. Exclude C44.xx)
- 5. At least 2 cancer visits based on the sum of all types of claims
- 6. Only include claims 6 months before death

## Step 2: Attribution

**Attribution:** Patients are attributed to the hospital/facility where the majority (> 50%) of all claims (inpatient (IP) + outpatient (OP) occur.


- Patients without any outpatient visits or inpatient stays in the last
   6 months before death are removed
- Patients who have no individual hospital/facility with more than one claim in last 6 months before death are removed
- If a patient does not have a total majority of all claims (IP + OP) >0.5 at a single hospital A:
  - Attribute to hospital with highest # of outpatient claims; if # OP claims tied
  - Attribute to hospital with highest # of inpatient claims; if #IP claims tied

Attribute to hospital with last IP claim before death

#### **Attribution Flowchart**




### Attribution Flowchart (continued)




## Step 3: Denominator

- The denominator for the chemo measure (NQF #0210), ICU measure (NQF #0213), and the not admitted to hospice measure (NQF #0215) is the number of patients attributed to the hospital/facility in the performance period.
- The denominator for the patients admitted to hospice for less than 3 days (NQF #0216) is the number of patients attributed to the hospital/facility in the performance period AND who were admitted to hospice in the last 6 months of life.

## Step 4: Numerator Calculation NQF #0210 (Chemo in Last 14 Days of Life)



### Step 4: Numerator Calculation NQF #0213 (ICU in the Last 30 Days of Life)




- 1. The patient counts toward the numerator if the patient has an inpatient claim including revenue codes 200-219 (ICU) for a hospitalization with an admission date within 30 days of death
- 2. If the admission date is beyond the 30 days of death but discharge date is within 30 days, and the inpatient claim for that hospitalization includes revenue codes 200-219 (ICU), then determine whether the ICU room change occurs within the 30 days window. If so, the patient counts toward the numerator.

#### ICU Revenue Codes

- 200 INTENSIVE CARE GENERAL CLASSIFICATION
- 201 INTENSIVE CARE SURGICAL
- 202 INTENSIVE CARE MEDICAL
- 203 INTENSIVE CARE PEDIATRIC
- 204 INTENSIVE CARE PSYCHIATRIC
- 206 INTENSIVE CARE INTERMEDIATE ICU
- 207 INTENSIVE CARE BURN CARE
- 208 INTENSIVE CARE TRAUMA
- 209 INTENSIVE CARE OTHER INTENSIVE CARE
- 210 CORONARY CARE GENERAL CLASSIFICATION
- 211 CORONARY CARE MYOCARDIAL INFARCTION
- 212 CORONARY CARE PULMONARY CARE
- 213 CORONARY CARE HEART TRANSPLANT
- 214 CORONARY CARE INTERMEDIATE CCU
- 219 CORONARY CARE OTHER CORONARY CARE


### Step 4: Numerator Calculation NQF #0215

(Not Admitted to Hospice in Last 6 Months of Life)



The patient counts toward the numerator if **no** hospice claims during the last 6 months of life.

### Step #4: Numerator Calculation NQF #216 (Admitted to Hospice for <= 3 Days)



**Note:** While official name of measure is, "Proportion of patients who died from cancer admitted to hospice for less than 3 days (NQF #0216), a review of NQF specifications clarifies that calculation is "Date of Death – Hospice Enrollment Date </= 3 Days".

## Step 5: Calculation of Performance Rates

- The performance rates are then determined for each measure by dividing the numerator by the denominator.
- These are measures for which a lower score indicates better quality:
  - Less chemo within last 14 days of life
  - Less intensive care utilization in last 30 days of life
  - MORE hospice care is desired in last 6 months of life, so measure is written to the reflect this: "Proportion of patients who died from cancer **not admitted** to hospice"
    - Want fewer patients not admitted to hospice
  - EARLIER enrollment in hospice is better, so measure is written, "Proportion of patients who died from cancer admitted to hospice for less than 3 days"

Want fewer patients admitted to hospice only in the last days of life

### Step 6: Stratification

**Stratification**: The ADCC tested and proposed the following stratification categories:

- Acute Hematology Lymphoblastic (diffuse) lymphoma, Burkitt lymphoma, anaplastic large cell lymphoma, acute lymphoblastic leukemia, acute myeloblastic leukemia, acute monoblastic/monocytic leukemia, acute erythroid leukemia, acute megakaryoblastic leukemia, and acute leukemia of unspecified cell type
- Non-Acute Hematology chronic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, and other hematological malignancies that are not included as "acute hematology"
- Solid Tumor All other cancers included in the cancer diagnoses codes used in determining the cohort for these measures

## Step 6: Stratification Codes

Acute Hematology	
ICD10	Description
C83.5	Lymphoblastic (diffuse) lymphoma
C83.7	Burkitt lymphoma
C84.6	Anaplastic large cell lymphoma
C84.7	Anaplastic large cell lymphoma
C91.0	Acute lymphoblastic leukemia
C92.0	Acute myeloblastic leukemia
C92.4	Acute myeloblastic leukemia
C92.5	Acute myeloblastic leukemia
C92.6	Acute myeloblastic leukemia
C92.A	Acute myeloblastic leukemia
C93.0	Acute monoblastic/monocytic leukemia
C94.0	Acute erythroid leukemia
C94.2	Acute megakaryoblastic leukemia
C95.0	Acute leukemia of unspecified cell type
Niama Assuta IIamaata	

#### Non-Acute Hematology

C81.xx - C 96.xx EXCLUDING the acute hematology codes above

#### **Solid Tumor**

All other cancer diagnoses in the cohort population (Refer to Cancer Diagnosis Codes tab)

Lisa Vinson, BS, BSN, RN, Program Lead, PCHQR Program, Inpatient VIQR Outreach and Education Support Contractor

#### **FY 2022 Confidential National Reporting**

### FY 2022 EOL Measures

- Confidential national reporting finalized in the FY 2020 IPPS/LTCH PPS Final Rule (84 FR 42523–42524)
- Original data collection period is July 1, 2019–June 30, 2020\*.
  - Collection period adjusted due to COVID-19
     PHE: July 1, 2019–December 31, 2019

<sup>\*1</sup>Q 2020 and 2Q 2020 claims data are excepted under the COVID-19 Public Health Emergency (PHE).

# 5 Objectives of Confidential National Reporting

- 1. Educate PCHs and other stakeholders about the measure.
- 2. Allow PCHs to review their measure results and data prior to public reporting.
- 3. Answer questions from PCHs and other stakeholders.
- 4. Test the production and reporting process.
- Identify potential additional technical changes to the measure specifications that might be needed.

Lisa Vinson, BS, BSN, RN, Program Lead, PCHQR Program, Inpatient VIQR Outreach and Education Support Contractor

#### **Accessing the EOL Confidential National Report**

## Getting Started: HQR Sign-In


Step 1: Navigate to the <u>HQR sign-in page</u>.

Step 2: Enter your HCQIS Access Roles and Profile (HARP) User ID and Password.

Step 3: Select Login.




### **Device Verification**




### **Verification Code**




### **Terms and Conditions**




### **HQR Home Page**



## **Program Reporting**



### **EOL Report Selections**



The Patient Summary Report is in a CSV file format.

fiscal_year	discharge_perf_period	id_number	provider_id	mbi	medical_record_number	bene_dob	bene_dod	patient_age
2022	07/01/2019-12/31/2019	1	123456	99999999999	99999999A	9/99/9999	9/99/9999	65 years and over

MBI = Medicare Beneficiary Identifier (11 digits)

DOB = date of birth

DOD = date of death

cancer_code_1	cancer_diagnosis	cancer_code_1_			chemo_treatment_	date_of_chemo_		icu_encounter_	date_of_icu_
_provider_id	_code_1	date	cancer_stratification	chemo_provider_id	code	treatment	icu_provider_id	code	service
999999	Α	9/99/9999	В	999999	Q codes	9/99/9999	999999	2XX	9/99/9999

Cancer diagnosis ICD-10 codes include specific ranges in categories C, D, J, R

A

Cancer Stratification selections include:

- Solid Tumor <u>or</u>
- Acute Hematology <u>or</u>
- Non-acute Hematology

В


hospice_provider_id	hospice_care_code	date_of_admission_to_hospice	hospice_days
999999	Q Codes	9/99/9999	

Hospice Days = numerical value will display if there is a date in the Date\_of\_Admission\_to Hospice column

chemo_pch_32_num	chemo_pch_32_den	icu_pch_33_num	icu_pch_33_den	hospice_pch_34_num	hospice_pch_34_den	3dh_pch_35_num	3dh_pch_35_den
Yes <u>or</u> No	Yes <u>or</u> No	Yes <u>or</u> No	Yes <u>or</u> No				

Yes = patient qualifies for inclusion in numerator and/or denominator No = patient does not qualify for inclusion in the numerator and/or denominator

# **EOL Measures Performance Report**



# **EOL Measures Performance Report**

Provider_ID	Fiscal_Year	Measure	Stratification	Provider_Type
999999	2022			Provider_Summary

- Measure individual rows for:
  - PCH-32
  - PCH-33
  - PCH-34
  - PCH-35



- Acute Hematology
  - Non-Acute Hematology
  - Solid Tumor
  - Overall

32	ACUTE HEMATOLOGY
32	NON-ACUTE HEMATOLOGY
32	SOLID TUMOR
32	OVERALL

# **EOL Measures Performance Report**

Numerator	Denominator	Measure_Rate	Footnote	Performance_Period _Start_Date	Performance_Period_End Date
17*	43*	40	5 <u>or</u> 7	 7/01/2019	12/31/2019

<sup>\*</sup>Numerical values are examples only.


#### Footnote Description:

5 = Results are not available for this reporting period


7 = No cases met the criteria for this measure

## Do You Have a Question About Your Report?

**QualityNet Question and Answer Tool** 



## **Select a Topic**



### **EOL** Resources

- QualityNet Questions and Answers Tool
  - Program > PCH > Cancer Hosp. Quality
     Reporting > Topic
    - Clinical Process/Oncology Care Measures (OCM) or
    - > Intermediate Clinical Outcome Measures
- QualityNet Measures Page (Coming Soon)
- QualityNet Data Collection Page

PCHQR Program: Overview of End-of-Life Measures

#### **Questions**

### **Continuing Education Approval**

This program has been approved for <u>credit</u> for the following boards:

#### National credit

Board of Registered Nursing (Provider #16578)

#### Florida-only credit

- Board of Clinical Social Work, Marriage & Family Therapy and Mental Health Counseling
- Board of Registered Nursing
- Board of Nursing Home Administrators
- Board of Dietetics and Nutrition Practice Council
- Board of Pharmacy

**Note:** To verify CE approval for any other state, license, or certification, please check with your licensing or certification board.

PCHQR Program: Overview of End-of-Life Measures

#### **Closing Remarks**

### **Disclaimer**

This presentation was current at the time of publication and/or upload onto the *Quality Reporting Center* and *QualityNet* websites. Medicare policy changes frequently. Any links to Medicare online source documents are for reference use only. In the case that Medicare policy, requirements, or guidance related to this presentation change following the date of posting, this presentation will not necessarily reflect those changes; given that it will remain as an archived copy, it will not be updated.

This presentation was prepared as a service to the public and is not intended to grant rights or impose obligations. Any references or links to statutes, regulations, and/or other policy materials included in the presentation are provided as summary information. No material contained therein is intended to take the place of either written laws or regulations. In the event of any conflict between the information provided by the presentation and any information included in any Medicare rules and/or regulations, the rules and regulations shall govern. The specific statutes, regulations, and other interpretive materials should be reviewed independently for a full and accurate statement of their contents.